Targeted inhibition of the JAK/STAT3 pathway has emerged as a promising therapeutic strategy for ALL (Jasek-Gajda et al., 2020; Bhansali et al., 2021). The gene discussed is STAT3; the disease is acute lymphoblastic leukemia.